Cardiff Oncology, Inc. — filing identity requires verification
The supplied filing is a Form 10-Q for the quarter ended September 30, 2014, filed November 6, 2014, by Trovagene, Inc., not Cardiff Oncology, Inc. The summary below reflects the filing text; verify the issuer and filing before relying on it.
Business context and reporting period
Trovagene was developing and commercializing precision cancer-monitoring technology based on urine-derived cell-free DNA. The unaudited report covers the three and nine months ended September 30, 2014, compared with the same periods in 2013. The company described its clinical programs and commercialization efforts as early stage and had generated minimal revenue.
Financial results and liquidity
| Metric | Three months ended Sept. 30, 2014 | Nine months ended Sept. 30, 2014 | Comparable 2013 period |
|---|---|---|---|
| Revenue | $57,199 | $223,780 | $43,756 quarterly; $211,879 nine-month |
| Operating expenses | $3.997 million | $10.665 million | $3.121 million quarterly; $8.053 million nine-month |
| Loss from operations | $3.940 million | $10.441 million | $3.078 million quarterly; $7.842 million nine-month |
| Net loss attributable to common shareholders | $5.381 million | $9.659 million | $4.407 million quarterly; $10.803 million nine-month |
| Loss per common share, basic and diluted | $0.28 | $0.51 | $0.25 quarterly; $0.66 nine-month |
Revenue was predominantly royalty income; nine-month 2014 revenue also included $10,000 in license fees. No diagnostic-test revenue was reported. A gross margin is not presented in the filing. Operating costs substantially exceeded revenue.
Research and development expense rose 81% to $4.830 million for the nine months, primarily as clinical collaborations expanded. Selling and marketing expense rose 47% to $1.700 million. General and administrative expense declined 2% to $4.135 million, partly because 2013 included a director-related stock-compensation charge. Interest expense increased to $454,082 from $6,931, reflecting borrowings. A $1.221 million nine-month gain from remeasurement of warrant liabilities reduced reported net loss; the third quarter instead included a $1.029 million noncash loss from that remeasurement.
At September 30, cash and cash equivalents were $31.164 million, total assets $32.762 million, and working capital $28.452 million. Cash was approximately $30.0 million at October 31; reported working capital then was $27.299 million. Operating activities used $8.861 million of cash during the first nine months, versus $5.462 million in 2013; investing activities used $236,000. Financing activities provided $14.423 million, primarily from new debt. The filing reports no cash-flow margin measure.
Total liabilities were $20.409 million. Debt had a $14.732 million carrying value at September 30, including $753,000 current and $13.979 million long term. The June 2014 $15 million term loan bears 7.07% interest, has interest-only payments through July 2015, then principal and interest payments through maturity on July 1, 2018. It is secured by company assets other than intellectual property, which is subject to a negative pledge, and includes covenants and a final fee of $1.05 million.
Material changes versus the prior comparable period
- Nine-month revenue increased modestly, while operating expenses rose 32%; operating loss increased to $10.441 million from $7.842 million.
- Nine-month net loss attributable to common shareholders improved by $1.144 million, mainly reflecting the warrant-liability fair-value gain, despite higher operating expenses and interest costs.
- Operating cash use increased by $3.398 million year over year. Cash nonetheless rose to $31.164 million, principally because of the 2014 debt financing; 2013 financing had instead included substantial equity and warrant proceeds.
- Working capital increased from $24.060 million at year-end 2013 to $28.452 million at September 30, 2014. Total liabilities increased from $6.764 million to $20.409 million, primarily reflecting the new term loan.
Outlook, risks, contingencies, and unusual items
- Management expected operating cash outflows for several years and stated that additional capital would be needed during 2016 to complete development and commercialization plans at projected spending levels. Additional financing was not assured; equity could dilute shareholders, and debt could impose restrictive covenants. Failure to obtain funding could delay, scale back, or discontinue programs or force unfavorable collaborations or asset dispositions.
- Management expected research and development, selling and marketing, general and administrative, and interest expenses to increase. Revenue timing from royalties, milestones, licenses, and future diagnostic tests was uncertain.
- A material disclosed risk was potential FDA regulation of laboratory-developed tests. FDA review or additional clinical studies could increase costs and delay or prevent commercialization; the filing said the regulatory outcome was uncertain.
- In May 2014, Trovagene assigned its miRNA patents to GenSignia IP Ltd. and received an exclusive, worldwide, royalty-free license back for the urine field, plus a low-single-digit royalty on GenSignia net sales and up to $6.5 million in sales-based milestones. Trovagene’s CEO was a GenSignia director; the filing states he did not participate in negotiations and recused himself from the board vote. The company recorded $10,000 of license revenue by September 30.
- The company expanded its office lease in May, adding 4,751 square feet and approximately $10,500 in monthly rent beginning October 2014. It also extended its Illumina research agreement in October 2014. These are subsequent-period developments reported in the filing.
- The company reported no material pending legal proceedings and no off-balance-sheet arrangements. Management concluded disclosure controls were effective as of September 30, 2014; no material quarterly change in internal control was reported.
Most important facts for investors to verify
- Confirm the issuer: the supplied text is Trovagene’s 2014 10-Q, not a Cardiff Oncology filing.
- Verify the $15 million loan’s payment schedule, collateral, covenants, prepayment fees, and $1.05 million final fee.
- Assess cash runway against the stated need for additional capital during 2016, ongoing operating cash burn, and management’s inability to assure financing.
- Track clinical validation, test commercialization, revenue generation, and potential FDA oversight of laboratory-developed tests.
- Review the warrant-liability valuation’s effect on reported earnings and the GenSignia transaction and related-party disclosures.